Important note: Information in this article was accurate in November 2003. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - November 2003
Atazanavir, is a once-daily protease inhibitor from Bristol Myers Squibb that was approved in the US in June 2003. The UK expanded access programme quickly enrolled, and unlike other countries the numbers for the programme were then capped. Access has now been extended through a new Individual Patient Supply (IPS) scheme, which allows doctors to request a drug for any patient who is considered in need. Administration costs are £360 per month – the licensed price is expected to be slightly lower.
Atazanavir is now available in 200mg and 150mg capsules, to enable patients to use a 300mg QD dose boosted with 100mg ritonavir.
Atazanavir is expected to be licensed in the European Union during the first quarter of 2004.
Doctors interested in this programme should contact Dr Ian Hitchcock at Bristol Myers Squibb on 020 8754 3684 or BMS main reception on 020 8572 7422.
031110
IB30409-15
©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
